title: Increased dietary potassium and magnesium attenuate experimental volume dependent hypertension possibly through endogenous sodium-potassium pump inhibitor.
abstract: We and others have shown that inhibition of cardiovascular muscle (CVM) cell Na+,K-ATPase activity (NKPTA) due to increased level of endogenous sodium potassium pump inhibitor (SPI) is involved in the mechanism of volume expanded (VE) experimental and human essential hypertension (HT). Since diets fortified with very high potassium (K) or very high magnesium (Mg) decrease blood pressure (BP), we have examined the effect of a moderate increase in dietary K alone and a moderate increase in dietary K and Mg on plasma levels of SPI, CVM cell NKPTA, and BP in reduced renal mass (RRM)-salt HT rats, a classical model of VE HT. Seventy Percent-RRM rats were divided in four dietary groups, (1) Na free and normal K and Mg (0Na-K-Mg); (2) normal Na, K and Mg (Na-K-Mg); (3) normal Na and high K (2 x normal), and normal Mg (Na-2K-Mg); and (4) normal Na and high K (2 x normal), and high Mg (2 x normal) (Na-2K-2Mg). As expected, compared to control 0Na-K-Mg rats, Na-K-Mg rats developed HT. Blood pressure increased significantly less in Na-2K-Mg rats whereas, BP did not increase in Na-2K-2Mg rats. Hypertension in NA-K-Mg rats was associated with an increase in plasma SPI and digitalis like factor (DIF) and a decrease in renal and myocardial NKPTA. However, doubling the Mg along with K in the diet (Na-2K-2Mg) normalized SPI and DIF and increased myocardial and renal NKPTA, compared to control 0Na-K-Mg rats. Also, compared to 0Na-K-Mg rats, water consumption, urine excretion, urinary sodium excretion urinary potassium excretion (U(Na)V), and (U(K)V) increased in the other three groups, more so in Na-2K-2Mg rats. These data show that K and Mg have additive effects in preventing an increase in SPI, thus probably preventing the BP increase in RRM rats.
authors.affiliation: Department of Physiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-44799, USA.
authors.forename: Motilal B
authors.initials: MB
authors.lastname: Pamnani
authors.forename: Howard J
authors.initials: HJ
authors.lastname: Bryant
authors.forename: David L
authors.initials: DL
authors.lastname: Clough
authors.forename: James F
authors.initials: JF
authors.lastname: Schooley
mesh_terms: D000818:Animals; D001794:Blood Pressure; D002298:Cardenolides; D004077:Digoxin / Q000097:blood*; D004195:Disease Models, Animal; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000033:anatomy & histology*; D008274:Magnesium / Q000627:therapeutic use*; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D009929:Organ Size; D017419:Potassium, Dietary / Q000627:therapeutic use*; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D012044:Regression Analysis; D012503:Saponins / Q000097:blood*; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D002298:Cardenolides; D017419:Potassium, Dietary; D012503:Saponins; C034504:digoxin-like factors; D004077:Digoxin; D000254:Sodium-Potassium-Exchanging ATPase; D008274:Magnesium